RU58841 from Amazon is unreliable, with users reporting no benefits and side effects like eye swelling and chest pain. Rudirect is recommended for purchasing in Europe.
Switching from topical to oral minoxidil caused acne breakouts, leading the user to revert to topical use. Finasteride was also used, but acne was suspected to be linked to oral minoxidil.
The user experiences immediate hair shedding linked to stress, unlike typical telogen effluvium, and is seeking answers. A suggestion was made to use spironolactone and topical minoxidil to address potential DHT-related shedding.
The user experienced red pimples and a rash from using topical minoxidil, possibly due to propylene glycol. Suggestions included seeing a dermatologist, switching to foam without propylene glycol, using Nizoral, and adjusting application timing.
The user experienced chest pain and increased heart rate after microneedling while using topical minoxidil for hair loss. They are unsure if minoxidil is effective without microneedling.
A person mistakenly drank an entire bottle of topical minoxidil, leading to ICU admission with shock and heart failure. The incident highlights the dangers of ingesting topical treatments and the importance of proper usage and dosage.
Spironolactone and finasteride are not recommended for women planning pregnancy due to birth defect risks. Both need to be stopped months before conception, and finasteride is generally not advised for women.
A user reported significant hair improvement using oral minoxidil, Rogaine 5%, and spironolactone but experienced worsening PMS. They seek advice on managing the PMS symptoms.
The conversation discusses skepticism about Breezula, a hair loss treatment, with the consensus that it's not a miracle cure but a maintenance drug that may work well with finasteride. Some users report side effects from finasteride, like sexual dysfunction, while hoping for better results from Breezula or RU58841 without such side effects.
Topical minoxidil can cause water retention, making the face appear swollen. Switching from liquid to foam and reducing application frequency may help; using dandelion root extract as a diuretic is also suggested.
OP is pausing hair loss treatments to focus on mental health due to anxiety and side effects from RU58841. They plan to try topical finasteride and minoxidil after recovering from pneumonia.
A user experienced telogen effluvium due to stress and was prescribed oral minoxidil and spironolactone, which initially worked. After stopping and restarting minoxidil, they experienced shedding but saw regrowth after discontinuing it again.
A user experienced severe side effects, including heart-related symptoms, after increasing their oral minoxidil dosage to 5 mg, leading them to stop the medication and seek medical advice. Many users advised against high doses of oral minoxidil, suggesting anxiety as a possible cause, and recommended consulting a doctor or switching to topical treatments.
Dutasteride capsules should not be bitten or opened due to their foul taste and potential caustic effects. Users shared experiences of accidentally biting capsules and the unpleasant taste, with some suggesting swallowing techniques to avoid this.
Breezula is a potential hair loss treatment, but recent updates suggest it may not be as promising as initially thought. Some users express skepticism about its effectiveness based on past results.
Oral minoxidil is causing significant blood pressure fluctuations and increased heart rate, leading the user to consider switching to topical minoxidil and tretinoin. The user plans to consult a cardiologist and is likely to stop using oral minoxidil.
Switching from oral minoxidil back to topical due to heart issues and palpitations. Users discuss experiences with minoxidil and finasteride, with mixed results and concerns about side effects.
The user experienced facial puffiness after switching from finasteride to dutasteride, which they believe is due to dutasteride. They are seeking advice on reversing this effect, considering factors like diet, exercise, and potential hormonal changes.
The conversation discusses the effectiveness of a hair loss treatment called CB (Breezula) in comparison to Pyrilutamide, and its potential when combined with Finasteride. There is uncertainty about when or if phase 3 trials for Breezula will begin.
The user is concerned about high prolactin levels and low testosterone levels after stopping finasteride for three weeks. They are considering resuming finasteride but are worried it might further increase prolactin levels.
A 24-year-old male experienced an increase in estradiol levels and symptoms like gynecomastia and excessive sweating after using Minoxidil for hair loss. His estradiol levels decreased after he stopped using Minoxidil.
The conversation is about the use and application of CB-03-01-2 (Breezula) for hair loss, including questions about its form, how to apply it, and the duration 10g would last. Specific treatments discussed are Minoxidil, finasteride, and RU58841.
Dutasteride works for most men, but some may experience worsening due to reasons like shedding, paranoia, non-androgenic alopecia, genetic variations, or smoking. Smoking can increase scalp DHT levels and damage follicles.
Cosmo Pharma plans to release Breezula, a hair loss treatment, with expected FDA approval in 2027, but concerns arise over its high potential cost of $225/month. Users express skepticism about its effectiveness compared to cheaper alternatives like finasteride and minoxidil.
A 20-year-old male experienced early hair thinning due to male pattern baldness and successfully thickened his hair using oral finasteride and topical minoxidil. The conversation highlights the importance of early action and overcoming fear of medication side effects.
PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.
Breezula's phase 3 results are expected soon, but its release is likely delayed until 2027 or 2028. The discussion highlights the need for more hair growth stimulants like AMP-303 and PP-405, as current treatments like Dutasteride effectively stop hair loss but don't regrow hair.
The conversation discusses Breezula, a hair loss treatment, and its Phase 3 clinical trial recruitment at 50 locations. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
The conversation is about managing allopregnanolone deficiency caused by 5-alpha-reductase inhibitors like finasteride or dutasteride. Specific treatments discussed for hair loss include Minoxidil, finasteride, and RU58841.